NCT03975036

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Exploratory Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Hydrochloride Combined With Pd-1 Antibody: An Open-Label, Single-center, Single-arm Study

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors

Detailed description

To observe the beneficial population and adverse reactions of anlotinib hydrochloride combined with pd-1 in the treatment of patients with advanced solid tumor, and to explore the safe and effective drug treatment dose in the combined program, so that more patients with advanced tumor with poor prognosis can benefit from the combined program

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	Anlotinib	Anlotinib Hydrochloride Capsules
DRUG	pd-1 antibody	Pembrolizumabinjection

Timeline

• Start date: 2019-04-08
• Primary completion: 2020-06-08
• Completion: 2021-07-08
• First posted: 2019-06-05
• Last updated: 2019-06-05

Locations

1 site across 1 country: China